Advanced Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Hepatocellular Cancer, Non-Small Cell Lung Cancer, Renal Cell Carcinoma
Conditions
Brief summary
The purpose of this study is to find a recommended schedule and dose range for Emibetuzumab when given with ramucirumab that may be safely given to participants with cancer. In Part A of this study, escalating doses of Emibetuzumab will be given in combination with a fixed dose of ramucirumab to evaluate the safety of the combination. After a recommended schedule and dose range of Emibetuzumab and ramucirumab has been established, Part B of the study will confirm safety and to see how well certain tumors respond to the combination of study drugs. The average amount of time on study is expected to be about 6 months.
Interventions
DRUGEmibetuzumab
Administered Intravenously (IV)
DRUGRamucirumab
Administered Intravenously (IV)
Sponsors
Eli Lilly and Company
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participants must have histological or cytological confirmed diagnosis of the following tumor types that is advanced and/or metastatic cancer and must be, in the judgment of the investigator, an appropriate participant for experimental therapy * Part A: Any type of solid tumor (all comer) * Part B1: Gastric or Gastroesophageal Junction (GEJ) adenocarcinoma * Part B2: Hepatocellular cancer (excluding fibrolamellar carcinoma) * Part B3: Renal cell carcinoma (any histology) * Part B4: Non-small cell lung cancer (squamous or non-squamous) * Have at least 1 measurable lesion outside of the central nervous system (CNS) whose presence is assessable using standard techniques by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. * Availability of a tumor sample taken after progression on the most recent line of systemic tumor therapy or willing to undergo a tumor biopsy pre-study treatment. * Have a performance status of ≤ 2 on the Eastern Cooperative Oncology Group (ECOG) scale in Part A and ≤ 1 on the ECOG scale in Part B. * Have adequate organ function. * Routine urinalysis showing ≤1+ protein or protein/creatinine ratio \<0.5. For proteinuria ≥2+ or urine protein/creatinine ratio ≥0.5, 24-hour urine must be collected and the level must be \<1 gram of protein in 24 hours for subject enrollment. * Have discontinued all previous cancer therapies and any agents that have not received regulatory approval for any indication, for at least 21 days or 5 halflives prior to study enrollment, whichever is shorter, and recovered from the acute effects for therapy. * Have an estimated life expectancy, in the judgment of the investigator, that will permit the participant to complete 8 weeks (2 cycles) of treatment. * Males and females with reproductive potential: Must agree to use medically approved contraceptive precautions during the study and for at least 3 months following the last dose of study drug. Females with childbearing potential must have had a negative serum pregnancy test 7 days before the first dose of study drug and must not be breast-feeding.
Exclusion criteria
* Have serious pre-existing medical conditions (at the discretion of the investigator, such as severe acute or chronic medical condition or laboratory abnormality that may increase the risk associated with study participation). * Have a history of hypertensive crisis or hypertensive encephalopathy or current poorly controlled hypertension despite standard medical management. * Participant has experienced any arterial thromboembolic event (ATE), including myocardial infarction, unstable angina pectoris, cerebrovascular accident, or transient ischemic attack, within 6 months prior to receiving study drugs. * Have a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolic event during the 3 months prior to receiving study drugs. * Are receiving therapeutic anticoagulation with warfarin, low-molecular weight heparin, or similar agents. Participants receiving prophylactic, low-dose anticoagulation therapy are eligible provided that they are on low-molecular weight heparin or oral factor Xa inhibitors. * The participant is receiving chronic therapy with nonsteroidal anti-inflammatory drugs or other antiplatelet agents. Aspirin use at doses up to 325 mg/day is permitted. * Have significant bleeding disorders, vasculitis, or had a significant bleeding episode from the gastrointestinal (GI) tract within 3 months prior to receiving study drugs. * Have a history of GI perforation and/or fistulae within 6 months prior to receiving study drugs. * Have congestive heart failure (CHF) New York Heart Association class ≥3 or symptomatic or poorly controlled cardiac arrhythmia. * Have undergone major surgery within 28 days prior to receiving study drugs. * Have a serious or nonhealing wound, peptic ulcer, or bone fracture within 28 days prior to receiving study drugs. * Have a known active fungal, bacterial, and/or known viral infection. Hepatocellular cancer participants with chronic viral (B or C) hepatitis are eligible if they retain adequate liver function. * Have liver cirrhosis with a Child-Pugh Stage of B or C. * Have symptomatic CNS malignancy (with the exception of medulloblastoma) or metastasis. * Have corrected QT (QTc) interval of \>470 milliseconds on screening electrocardiogram (ECG). * Have received previous treatment with ramucirumab or Emibetuzumab, except for participants enrolled in cohort B1 (Gastric or GEJ adenocarcinoma) and B4 (non- small cell lung cancer) who may have received previous ramucirumab treatment. * Known hypersensitivity to any of the treatment components of ramucirumab or Emibetuzumab. * Have a second primary malignancy that, in the judgment of the investigator and sponsor, may affect the interpretation of results. * Are pregnant or breastfeeding. * For Part B4 (non-small cell lung cancer) only: * The participant has radiologically documented evidence of major blood vessel invasion or encasement by cancer * Participants with a history of gross hemoptysis within 2 months prior to study treatment * The participant has radiographic evidence of intratumor cavitation, regardless of tumor histology
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) | Baseline through Cycle 1 (28 day cycle) | DLT is defined as an adverse event during Cycle1 that is possibly, probably, or definitely related to treatment with Emibetuzumab in combination with fixed regimen of Ramucirumab & fulfills any 1 of the following criterion using NCI CTCAE Version 4.03: Grade 3 non-hematological toxicity. Exceptions will be made for:Nausea, vomiting, diarrhea, constipation, or skin rash that persists for ≤3 days following appropriate supportive care intervention. Grade 3 hypertension in which systolic BP ≥160 mmHg and/or diastolic BP ≥100 mmHg persist \<7 days after intensified antihypertensive therapy is initiated. Grade 4 hematological toxicity of ≥7 days duration. ≥Grade 3 thrombocytopenia with ≥Grade 2 bleeding. Any febrile neutropenia. Any other significant toxicity deemed by the primary investigator & Lilly clinical research personnel to be dose-limiting (eg, any toxicity that is possibly related to the study medication that requires the withdrawal of participant from study Cycle1). |
| Part B: Percentage of Participants Who Exhibit Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)] | Baseline through Measured Progressive Disease or Death (Up to 17 months) | ORR is the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Part B: Percentage of Participants Who Exhibit Stable Disease (SD) or Confirmed Response (CR) or Partial Response (PR) (Disease Control Rate [DCR]) | Baseline through Measured Progressive Disease (Up to 17 months) | DCR is the proportion of participants who exhibit a SD or confirmed CR or PR relative to baseline. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. Progressive disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. |
| Part B: Progression Free Survival (PFS) | Baseline to Measured Progressive Disease or Death (Up to 17 Months) | PFS was defined as the time from the date of first dose of study drug until first observation of objective (radiographically documented) PD as defined by RECIST v1.1 or death from any cause, whichever comes first. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. |
| Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) From Time Zero to Tlast of Emibetuzumab | Cycle 1: Day1 Predose, End of infusion, 3 Hours (h), 5h, 8h, 21h, 168h, 334h, 335h and 336h Post dose | Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) from time zero to tlast of Emibetuzumab. |
| Number of Participants With Treatment Emergent Anti-Ramucirumab Antibodies | Baseline through 46 Months | Participants were considered as treatment-emergent anti drug antibodies (TE ADA) positive if there is a ≥4-fold increase from baseline when ADAs were detected at baseline. If no ADAs were detected at baseline, TE ADA were defined as those with a titer 2 fold (1 dilution) greater than the minimum required dilution (MRD) of the screening assay (1:10 for anti-ramucirumab antibodies). |
| Number of Participants With Treatment Emergent Anti-Emibetuzumab Antibodies | Baseline through 46 Months | Participants were considered as treatment-emergent anti drug antibodies (TE ADA) positive if there is a ≥4-fold increase from baseline when ADAs were detected at baseline. If no ADAs were detected at baseline, TE ADA were defined as those with a titer 2 fold (1 dilution) greater than the minimum required dilution (MRD) of the screening assay (1:4 for anti-emibetuzumab antibodies). |
| Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of Ramucirumab | Cycle 1: Day1 Predose, End of infusion, 3 Hours (h), 5h, 8h, 21h, 168h and 336h Post dose | Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of Ramucirumab. |
| Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Ramucirumab | Cycle 1: Day1 Predose, End of infusion, 3 Hours (h), 5h, 8h, 21h, 168h and 336h Post dose | Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Ramucirumab. |
| Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Emibetuzumab | Cycle 1: Day1 Predose, End of infusion, 3 Hours (h), 5h, 8h, 21h, 168h, 334h, 335h and 336h Post dose | Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Emibetuzumab. |
Countries
United States
Participant flow
Recruitment details
Part A: Completers are those who have completed one cycle of treatment. Part B: Completers are those who 1)Have measurable disease at baseline and at least one post-baseline tumor assessment; and 2) Were treated until PD or death, or discontinued due to an AE and completed the required follow-up.
Pre-assignment details
Two part study, Part A with 2 cohorts (750 milligram (mg), 2000mg) & Part B with four tumor specific cohorts (gastric, hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC)).
Participants by arm
| Arm | Count |
|---|---|
| Part A - 750 mg Emibetuzumab Participants received 8 mg/kg Ramucirumab followed by 750 mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle. | 3 |
| Part A - 2000 mg Emibetuzumab Participants received 8 mg/kg Ramucirumab followed by 2000 mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle. | 3 |
| Part B - Gastric Participants received 8 mg/kg Ramucirumab followed by 750mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle. | 16 |
| Part B - HCC Participants received 8 mg/kg Ramucirumab followed by 750mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle. | 45 |
| Part B - RCC Participants received 8 mg/kg Ramucirumab followed by 750mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle. | 15 |
| Part B - NSCLC Participants received 8 mg/kg Ramucirumab followed by 750mg Emibetuzumab given as intravenous (IV) infusion on days 1 and 15 of 28 days cycle. | 15 |
| Total | 97 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 |
|---|---|---|---|---|---|---|---|
| Overall Study | Clinical Progression | 0 | 0 | 0 | 1 | 0 | 0 |
| Overall Study | Death | 0 | 0 | 1 | 1 | 1 | 0 |
| Overall Study | No Post-Baseline Tumor Assesment | 0 | 0 | 1 | 2 | 0 | 0 |
| Overall Study | Physician Decision | 0 | 0 | 1 | 1 | 0 | 0 |
| Overall Study | Withdrawal by Subject | 0 | 0 | 0 | 1 | 2 | 2 |
Baseline characteristics
| Characteristic | Part A - 750 mg Emibetuzumab | Total | Part B - NSCLC | Part B - RCC | Part B - HCC | Part B - Gastric | Part A - 2000 mg Emibetuzumab |
|---|---|---|---|---|---|---|---|
| Age, Continuous | 41.3 years STANDARD_DEVIATION 20.6 | 62.0 years STANDARD_DEVIATION 10.4 | 59.9 years STANDARD_DEVIATION 8.6 | 63.1 years STANDARD_DEVIATION 10.1 | 63.4 years STANDARD_DEVIATION 9.5 | 62.6 years STANDARD_DEVIATION 9.1 | 62.0 years STANDARD_DEVIATION 13.5 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 6 Participants | 0 Participants | 2 Participants | 3 Participants | 1 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 3 Participants | 84 Participants | 14 Participants | 13 Participants | 36 Participants | 15 Participants | 3 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 9 Participants | 2 Participants | 0 Participants | 7 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 6 Participants | 1 Participants | 0 Participants | 3 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 3 Participants | 76 Participants | 11 Participants | 14 Participants | 32 Participants | 14 Participants | 2 Participants |
| Region of Enrollment United States | 3 Participants | 97 Participants | 15 Participants | 15 Participants | 45 Participants | 16 Participants | 3 Participants |
| Sex: Female, Male Female | 3 Participants | 27 Participants | 6 Participants | 3 Participants | 11 Participants | 4 Participants | 0 Participants |
| Sex: Female, Male Male | 0 Participants | 70 Participants | 9 Participants | 12 Participants | 34 Participants | 12 Participants | 3 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk |
|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 3 | 0 / 3 | 3 / 16 | 4 / 45 | 1 / 15 | 1 / 15 |
| other Total, other adverse events | 3 / 3 | 3 / 3 | 15 / 16 | 45 / 45 | 15 / 15 | 14 / 15 |
| serious Total, serious adverse events | 2 / 3 | 2 / 3 | 4 / 16 | 19 / 45 | 5 / 15 | 3 / 15 |
Outcome results
Primary
Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)
DLT is defined as an adverse event during Cycle1 that is possibly, probably, or definitely related to treatment with Emibetuzumab in combination with fixed regimen of Ramucirumab & fulfills any 1 of the following criterion using NCI CTCAE Version 4.03: Grade 3 non-hematological toxicity. Exceptions will be made for:Nausea, vomiting, diarrhea, constipation, or skin rash that persists for ≤3 days following appropriate supportive care intervention. Grade 3 hypertension in which systolic BP ≥160 mmHg and/or diastolic BP ≥100 mmHg persist \<7 days after intensified antihypertensive therapy is initiated. Grade 4 hematological toxicity of ≥7 days duration. ≥Grade 3 thrombocytopenia with ≥Grade 2 bleeding. Any febrile neutropenia. Any other significant toxicity deemed by the primary investigator & Lilly clinical research personnel to be dose-limiting (eg, any toxicity that is possibly related to the study medication that requires the withdrawal of participant from study Cycle1).
Time frame: Baseline through Cycle 1 (28 day cycle)
Population: All participants who received at least one dose of Emibetuzumab in Part A \& Part B.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part A - 750 mg Emibetuzumab | Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) | 0 Participants |
| Part A - 2000 mg Emibetuzumab | Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) | 0 Participants |
| Part B - Gastric | Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) | 0 Participants |
| Part B - HCC | Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) | 0 Participants |
| Part B - RCC | Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) | 0 Participants |
| Part B - NSCLC | Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) | 0 Participants |
Primary
Part B: Percentage of Participants Who Exhibit Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)]
ORR is the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
Time frame: Baseline through Measured Progressive Disease or Death (Up to 17 months)
Population: All participants who received at least one dose of Emibetuzumab in Part B.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Part A - 750 mg Emibetuzumab | Part B: Percentage of Participants Who Exhibit Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)] | 6.3 percentage of participants |
| Part A - 2000 mg Emibetuzumab | Part B: Percentage of Participants Who Exhibit Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)] | 6.7 percentage of participants |
| Part B - Gastric | Part B: Percentage of Participants Who Exhibit Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)] | 0 percentage of participants |
| Part B - HCC | Part B: Percentage of Participants Who Exhibit Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)] | 6.7 percentage of participants |
Secondary
Number of Participants With Treatment Emergent Anti-Emibetuzumab Antibodies
Participants were considered as treatment-emergent anti drug antibodies (TE ADA) positive if there is a ≥4-fold increase from baseline when ADAs were detected at baseline. If no ADAs were detected at baseline, TE ADA were defined as those with a titer 2 fold (1 dilution) greater than the minimum required dilution (MRD) of the screening assay (1:4 for anti-emibetuzumab antibodies).
Time frame: Baseline through 46 Months
Population: All participants who received at least one dose of Emibetuzumab and had evaluable immunogenicity samples.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part A - 750 mg Emibetuzumab | Number of Participants With Treatment Emergent Anti-Emibetuzumab Antibodies | 0 Participants |
| Part A - 2000 mg Emibetuzumab | Number of Participants With Treatment Emergent Anti-Emibetuzumab Antibodies | 0 Participants |
| Part B - Gastric | Number of Participants With Treatment Emergent Anti-Emibetuzumab Antibodies | 0 Participants |
| Part B - HCC | Number of Participants With Treatment Emergent Anti-Emibetuzumab Antibodies | 3 Participants |
| Part B - RCC | Number of Participants With Treatment Emergent Anti-Emibetuzumab Antibodies | 0 Participants |
| Part B - NSCLC | Number of Participants With Treatment Emergent Anti-Emibetuzumab Antibodies | 0 Participants |
Secondary
Number of Participants With Treatment Emergent Anti-Ramucirumab Antibodies
Participants were considered as treatment-emergent anti drug antibodies (TE ADA) positive if there is a ≥4-fold increase from baseline when ADAs were detected at baseline. If no ADAs were detected at baseline, TE ADA were defined as those with a titer 2 fold (1 dilution) greater than the minimum required dilution (MRD) of the screening assay (1:10 for anti-ramucirumab antibodies).
Time frame: Baseline through 46 Months
Population: All participants who received at least one dose of ramucirumab and had evaluable immunogenicity samples.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part A - 750 mg Emibetuzumab | Number of Participants With Treatment Emergent Anti-Ramucirumab Antibodies | 1 Participants |
| Part A - 2000 mg Emibetuzumab | Number of Participants With Treatment Emergent Anti-Ramucirumab Antibodies | 0 Participants |
| Part B - Gastric | Number of Participants With Treatment Emergent Anti-Ramucirumab Antibodies | 0 Participants |
| Part B - HCC | Number of Participants With Treatment Emergent Anti-Ramucirumab Antibodies | 4 Participants |
| Part B - RCC | Number of Participants With Treatment Emergent Anti-Ramucirumab Antibodies | 1 Participants |
| Part B - NSCLC | Number of Participants With Treatment Emergent Anti-Ramucirumab Antibodies | 0 Participants |
Secondary
Part B: Percentage of Participants Who Exhibit Stable Disease (SD) or Confirmed Response (CR) or Partial Response (PR) (Disease Control Rate [DCR])
DCR is the proportion of participants who exhibit a SD or confirmed CR or PR relative to baseline. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. Progressive disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
Time frame: Baseline through Measured Progressive Disease (Up to 17 months)
Population: All participants who received at least one dose of Emibetuzumab in Part B.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Part A - 750 mg Emibetuzumab | Part B: Percentage of Participants Who Exhibit Stable Disease (SD) or Confirmed Response (CR) or Partial Response (PR) (Disease Control Rate [DCR]) | 50 percentage of participants |
| Part A - 2000 mg Emibetuzumab | Part B: Percentage of Participants Who Exhibit Stable Disease (SD) or Confirmed Response (CR) or Partial Response (PR) (Disease Control Rate [DCR]) | 60 percentage of participants |
| Part B - Gastric | Part B: Percentage of Participants Who Exhibit Stable Disease (SD) or Confirmed Response (CR) or Partial Response (PR) (Disease Control Rate [DCR]) | 46.7 percentage of participants |
| Part B - HCC | Part B: Percentage of Participants Who Exhibit Stable Disease (SD) or Confirmed Response (CR) or Partial Response (PR) (Disease Control Rate [DCR]) | 86.7 percentage of participants |
Secondary
Part B: Progression Free Survival (PFS)
PFS was defined as the time from the date of first dose of study drug until first observation of objective (radiographically documented) PD as defined by RECIST v1.1 or death from any cause, whichever comes first. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
Time frame: Baseline to Measured Progressive Disease or Death (Up to 17 Months)
Population: All participants who received at least one dose of Emibetuzumab in part B. Censored participants in Part B- Gastric = 4; Part B - HCC = 15; Part B - RCC = 7; Part - B NSCLC = 4;
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part A - 750 mg Emibetuzumab | Part B: Progression Free Survival (PFS) | 1.64 months |
| Part A - 2000 mg Emibetuzumab | Part B: Progression Free Survival (PFS) | 5.42 months |
| Part B - Gastric | Part B: Progression Free Survival (PFS) | 2.92 months |
| Part B - HCC | Part B: Progression Free Survival (PFS) | 6.57 months |
Secondary
Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) From Time Zero to Tlast of Emibetuzumab
Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) from time zero to tlast of Emibetuzumab.
Time frame: Cycle 1: Day1 Predose, End of infusion, 3 Hours (h), 5h, 8h, 21h, 168h, 334h, 335h and 336h Post dose
Population: All participants who received at least one dose of Emibetuzumab and had evaluable PK samples in Part A \& Part B.~Per protocol, analysis was performed per each dose irrespective of study parts.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Part A - 750 mg Emibetuzumab | Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) From Time Zero to Tlast of Emibetuzumab | 29800 Microgram * hour per milliliter(µg*h/mL) | Geometric Coefficient of Variation 26 |
| Part A - 2000 mg Emibetuzumab | Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) From Time Zero to Tlast of Emibetuzumab | 86500 Microgram * hour per milliliter(µg*h/mL) | Geometric Coefficient of Variation 25 |
Secondary
Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Ramucirumab
Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Ramucirumab.
Time frame: Cycle 1: Day1 Predose, End of infusion, 3 Hours (h), 5h, 8h, 21h, 168h and 336h Post dose
Population: Noncompartmental PK parameters were not generated for Ramucirumab due to inadequate PK sampling.
Secondary
Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of Ramucirumab
Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of Ramucirumab.
Time frame: Cycle 1: Day1 Predose, End of infusion, 3 Hours (h), 5h, 8h, 21h, 168h and 336h Post dose
Population: Noncompartmental PK parameters were not generated for Ramucirumab due to inadequate PK sampling.
Secondary
Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Emibetuzumab
Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Emibetuzumab.
Time frame: Cycle 1: Day1 Predose, End of infusion, 3 Hours (h), 5h, 8h, 21h, 168h, 334h, 335h and 336h Post dose
Population: All participants who received at least one dose of Emibetuzumab and had evaluable PK samples in Part A \& Part B.~Per protocol analysis was performed per each dose irrespective of the study parts.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Part A - 750 mg Emibetuzumab | Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Emibetuzumab | 210 Microgram per milliliter (µg/mL) | Geometric Coefficient of Variation 27 |
| Part A - 2000 mg Emibetuzumab | Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Emibetuzumab | 575 Microgram per milliliter (µg/mL) | Geometric Coefficient of Variation 33 |